A single-centre study evaluating a geriatric screening tool in oncology phase I trial patients

Cancer Rep (Hoboken). 2024 Jun;7(6):e2083. doi: 10.1002/cnr2.2083.

Abstract

Background: Though cancer is more prevalent in the older population, this patient group are underrepresented in phase I oncology trials.

Aims: We evaluated the use of a geriatric screening tool (SAOP3) in patients of 70 years of age or older who attended a Phase I Clinical Trials Unit, with the aim of assessing the feasibility of the tool and identifying potential unmet needs in this patient group.

Methods: Twenty-two patients over the age of 70 completed the SAOP3 questionnaire. Geriatric impairments and needs were analysed with descriptive statistics. Qualitative responses were grouped in themes using structured thematic analysis.

Results: All of patients triggered at least 1 geriatric domain, most commonly mobility. Six core themes were identified as being important to the patient including family, friends and positivity. On cognition assessment over 20% of patients triggered as requiring further cognitive assessment. The group had a relatively high screen fail risk.

Conclusion: In conclusion, routine geriatric screening withSAOP3 was feasible and identified areas of patient need. Results highlight the prevalence of psychological distress and cognitive impairment. Geriatric screening offers an opportunity for prehabilitation prior to trial and support during trial participation to optimise safety and improve trial access.

Keywords: clinical trial; geriatric assessment; phase I.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Clinical Trials, Phase I as Topic*
  • Cognitive Dysfunction / diagnosis
  • Cognitive Dysfunction / epidemiology
  • Cognitive Dysfunction / psychology
  • Feasibility Studies
  • Female
  • Geriatric Assessment* / methods
  • Humans
  • Male
  • Mass Screening / methods
  • Neoplasms* / psychology
  • Surveys and Questionnaires